OIS@ASRS

M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, introduces a promising new technology that could enable much earlier…

John Edwards, CEO of Drusolv Therapeutics, lays out the company’s plan to use statins as a treatment for intermediate AMD. The firm is based off…

Remis Bistras, CEO of ProFarma, lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion…

Shelley Boyd, MD, president and chief scientific officer, says Translatum Medicus Inc. has raised its first angel round based upon the potential of the company’s…

John Freshley, president and CEO of ONL Therapeutics, updates OIS on the development program of Fas inhibitors. The company’s lead product is ONL 1204, which…

Reenie McCarthy, CEO of Stealth BioTherapeutics, introduces the company’s early-stage clinical program testing mitochondrial medicine as treatment for ophthalmic conditions. McCarthy details three ongoing clinical…

Joseph Gardner, president and CEO, introduces the company’s first-in-class pipeline targeting the Tie2/VE-PTP pathway. Gardner delivers an extensive overview of Aerpio’s AKB-9778, a novel small…

Jason Slakter, MD, CEO, lays out a pivotal year for Ohr Pharmaceutical’s squalamine lactate, an intracellular treatment for wet AMD. Dr. Slakter reviews early results…

OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the…

Candor, passion, realism, talent, flexibility, self awareness, humility, and focus are all qualities seed-stage benefactors look for in a start-up founder, fund managers said at…

Deb Jorn, EVP, corporate development, shares promising results from three clinical trials of the company’s Durasert delivery product. She also shares pSivida’s plans to file…

Dan Myers, CEO, discusses the promise and challenges facing the Alimera’s development of Illuvien for the treatment of DME. He shares results from the firm’s…